Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lee M Kaplan

Showing results (41-50 of 91) with videos related to

Pageof 10
Sort By:
Obesity Surgery|November 24, 2023
IFSO Consensus on Definitions and Clinical Practice Guidelines for Obesity Management-an International Delphi StudyPaulina Salminen, Lilian Kow, Ali Aminian, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 10, 2013
Bone loss after bariatric surgery: discordant results between DXA and QCT bone densityElaine W Yu, Mary L Bouxsein, Adam E Roy, et al.
JACC. Heart Failure|October 25, 2024
Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes TrialMikhail N Kosiborod, Elke Platz, Sean Wharton, et al.
Obesity (Silver Spring, Md.)|April 28, 2009
Endoscopic interventions for weight loss surgeryJames C Ellsmere, Christopher C Thompson, William R Brugge, et al.
The New England Journal of Medicine|June 27, 2023
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 TrialAnia M Jastreboff, Lee M Kaplan, Juan P Frías, et al.
Obesity Research|April 1, 2005
Coding and reimbursement for weight loss surgery: best practice recommendationsLee M Kaplan, John A Fallon, Edward C Mun, et al.
Diabetes, Obesity & Metabolism|October 15, 2025
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trialsKathryn Giblin, Lee M Kaplan, Virend K Somers, et al.
Diabetes, Obesity & Metabolism|November 4, 2025
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1)Carel W le Roux, Sean Wharton, Biykem Bozkurt, et al.
Diabetes|December 11, 2012
Inverse regulation of inflammation and mitochondrial function in adipose tissue defines extreme insulin sensitivity in morbidly obese patientsMohammed Qatanani, Yejun Tan, Radu Dobrin, et al.
Diabetes, Obesity & Metabolism|November 11, 2025
Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetesSean Wharton, Carel W le Roux, Biykem Bozkurt, et al.
Pageof 10

Showing results (41-50 of 91) with videos related to

Sort By:
Pageof 10
Obesity Surgery|November 24, 2023
IFSO Consensus on Definitions and Clinical Practice Guidelines for Obesity Management-an International Delphi StudyPaulina Salminen, Lilian Kow, Ali Aminian, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|August 10, 2013
Bone loss after bariatric surgery: discordant results between DXA and QCT bone densityElaine W Yu, Mary L Bouxsein, Adam E Roy, et al.
JACC. Heart Failure|October 25, 2024
Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes TrialMikhail N Kosiborod, Elke Platz, Sean Wharton, et al.
Obesity (Silver Spring, Md.)|April 28, 2009
Endoscopic interventions for weight loss surgeryJames C Ellsmere, Christopher C Thompson, William R Brugge, et al.
The New England Journal of Medicine|June 27, 2023
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 TrialAnia M Jastreboff, Lee M Kaplan, Juan P Frías, et al.
Obesity Research|April 1, 2005
Coding and reimbursement for weight loss surgery: best practice recommendationsLee M Kaplan, John A Fallon, Edward C Mun, et al.
Diabetes, Obesity & Metabolism|October 15, 2025
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trialsKathryn Giblin, Lee M Kaplan, Virend K Somers, et al.
Diabetes, Obesity & Metabolism|November 4, 2025
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1)Carel W le Roux, Sean Wharton, Biykem Bozkurt, et al.
Diabetes|December 11, 2012
Inverse regulation of inflammation and mitochondrial function in adipose tissue defines extreme insulin sensitivity in morbidly obese patientsMohammed Qatanani, Yejun Tan, Radu Dobrin, et al.
Diabetes, Obesity & Metabolism|November 11, 2025
Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetesSean Wharton, Carel W le Roux, Biykem Bozkurt, et al.
Pageof 10